Atypical antipsychotics and inverse agonism at 5-HT2 receptors

Current Pharmaceutical Design

Volumn 21, Issue 26, 2015, Pages 3732-3738

  Sullivan, Laura C ^a   Clarke, William P ^a   Berg, Kelly A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

5 HT2Areceptors; 5 HT2C receptors; Antipsychotic drugs; Atypical antipsychotic drugs; Constitutive activity; Inverse agonism; Schizophrenia; Serotonin

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; ILOPERIDONE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; ZIPRASIDONE; NEUROLEPTIC AGENT; SEROTONIN 2 AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ARTICLE; DRUG EFFICACY; HUMAN; INVERSE AGONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; STUDY DESIGN; ANIMAL; BIOLOGICAL MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DISCOVERY; DRUG INVERSE AGONISM; HUMANS; MODELS, BIOLOGICAL; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84942155413     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150605111236     Document Type: Article

References (92)

1. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71(4): 533-54.
2. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998; 44(3): 151-62.
3. Van Oekelen D, Luyten WH, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 2003; 72(22): 2429-49.
4. Di Pietro NC, Seamans JK. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 2007; 40 (Suppl 1): S27-33.
5. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007; 32(8): 1715-26.
6. Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001; 299(1): 268-76.
7. Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003; 28(2): 402-12.
8. Berg KA, Harvey JA, Spampinato U, Clarke WP. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog Brain Res 2008; 172: 287-305.
9. Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev 2011; 15(4): 269-81.
10. Aloyo VJ, Berg KA, Spampinato U, Clarke WP, Harvey JA. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol Ther 2009; 121(2): 160-73.
11. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008; 108(5): 1614-41.
12. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38(8): 1083-152.
13. Berg KA, Stout BD, Maayani S, Clarke WP. Differences in rapid desensitization of 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor-mediated phospholipase C activation. Pharmacol Exp Ther 2001; 299(2): 593-602.
14. Berg KA, Clarke WP, Sailstad C, Saltzman A, Maayani S. Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Mol Pharmacol 1994; 46(3): 477-84.
15. Raymond JR, Mukhin YV, Gelasco A, et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 2001; 92(2-3): 179-212.
16. Noda M, Higashida H, Aoki S, Wada K. Multiple signal transduction pathways mediated by 5-HT receptors. Mol Neurobiol 2004; 29(1): 31-9.
17. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008; 195(1): 198-213.
18. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71(4): 533-54.
19. Berg KA, Maayani S, Goldfarb J, Clarke WP. Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann N Y Acad Sci 1998; 861: 104-10.
20. Cerione RA, Sibley DR, Codina J, et al. Reconstitution of a hormone-sensitive adenylate cyclase system. The pure betaadrenergic receptor and guanine nucleotide regulatory protein confer hormone responsiveness on the resolved catalytic unit. J Biol Chem 1984; 259(16): 9979-82.
21. Cerione RA, Codina J, Benovic JL, Lefkowitz RJ, Birnbaumer L, Caron MG. The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 1984; 23(20): 4519-25.
22. Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci 1989; 86(19): 7321-5.
23. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001; 15(3): 598-611.
24. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 2004; 65(1): 2-11.
25. Seifert R, Wenzel-Seifert K. Constitutive activity of G-proteincoupled receptors: cause of disease and common property of wildtype receptors. Naunyn Schmiedebergs Arch Pharmacol 2002; 366(5): 381-416.
26. Leff P, Scaramellini C, Law C, McKechnie K. A three-state receptor model of agonist action. Trends Pharmacol Sci 1997; 18(10): 355-62.
27. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007; 320(1): 1-13.
28. Clarke WP, Chavera TA, Silva M, Sullivan LC, Berg KA. Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol 2013; 170(3): 532-45.
29. Tian WN, Duzic E, Lanier SM, Deth RC. Determinants of alpha 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol Pharmacol 1994; 45: 524-31.
30. McLoughlin DJ, Strange PG. Mechanisms of agonism and inverse agonism at serotonin 5-HT1A receptors. J Neurochem 2000; 74: 347-57.
31. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272: 22330-9.
32. Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 1999; 55(5): 863-72.
33. Black JW, Leff P, Shankley NP, Wood J. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 1985; 84(2): 561-71.
34. Hoyer D, Boddeke HW. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 1993; 14(7): 270-5.
35. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 1996; 48(3): 413-63.
36. Berg KA, Harvey JA, Spampinato U, Clarke WP. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol Sci 2005; 26(12): 625-30.
37. Harvey JA. Role of the serotonin 5-HT(2A) receptor in learning. Learn Mem 2003; 10(5): 355-62.
38. Wilbanks AM, Laporte SA, Bohn LM, Barak LS, Caron MG. Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. Biochemistry 2002; 41(40): 11981-9.
39. Barker EL, Westphal RS, Schmidt D, Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 1994; 269(16): 11687-90.
40. Herrick-Davis K, Grinde E, Niswender CM. Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem. 1999; 73(4): 1711-7.
41. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity J Biol Chem 1999; 274(14): 9472-8.
42. Westphal RS, Backstrom JR, Sanders-Bush E. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. Mol Pharmacol 1995; 48(2): 200-5.
43. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000; 295(1): 226-32.
44. Egan C, Herrick-Davis K, Teitler M. Creation of a constitutively activated state of the 5-HT2A receptor by site-directed mutagenesis: revelation of inverse agonist activity of antagonists. Ann N Y Acad Sci 1998; 861: 136-9.
45. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 2002; 277(13): 11441-9.
46. Teitler M, Herrick-Davis K, Purohit A. Constitutive activity of Gprotein coupled receptors: emphasis on serotonin receptors. Curr Top Med Chem 2002; 2(6): 529-38.
47. Aloyo VJ, Dave KD, Rahman T, Harvey JA. Selective and divergent regulation of cortical 5-HT(2A) receptors in rabbit. J Pharmacol Exp Ther 2001; 299(3): 1066-72.
48. Dave KD, Harvey JA, Aloyo VJ. The time-course for up-and down-regulation of the cortical 5-hydroxytryptamine (5-HT)2A receptor density predicts 5-HT2A receptor-mediated behavior in the rabbit. J Pharmacol Exp Ther 2007; 323(1): 327-35.
49. Millan MJ, Dekeyne A, Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998; 37(7): 953-5.
50. Di Giovanni G, De Deurwaerdére P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 1999; 91(2): 587-97.
51. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999; 38(8): 1195-205.
52. Gobert A, Rivet JM, Lejeune F, et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 2000; 36(3): 205-21.
53. De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004; 24(13): 3235-41.
54. Schmidt CJ, Fadayel GM. The selective 5-HT2A receptor antagonist, MDL 100, 907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995; 273(3): 273-9.
55. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress-and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 2006; 31(2): 265-77.
56. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 113(2): 296-320.
57. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 2008; 172: 7-44.
58. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008; 172: 177-97.
59. Theodoridou A, Rössler W. Disease burden and disability-adjusted life years due to schizophrenia and psychotic disorders. In: Preedy VR, Watson RR, Eds. Handbook of Disease Burdens and Quality of Life Measures, Pt. 2, 2.6. New York: Springer Science and Business Media 2010; pp. 1493-1507.
60. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10(1): 79-104.
61. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010; 81(5): 617-22.
62. MacDonald GJ, Bartolomé JM. A decade of progress in the discovery and development of 'atypical' antipsychotics. Prog Med Chem 2010; 49: 37-80.
63. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14(3): 152-64.
64. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13(1): 27-35.
65. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76(5): 1521-31.
66. Cussac D, Newman-Tancredi A, Nicolas JP, Boutin JA, Millan MJ. Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. Naunyn Schmiedebergs Arch Pharmacol 2000; 361(5): 549-54.
67. Westphal RS, Sanders-Bush E. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol 1994; 46(5): 937-42.
68. Navailles S, De Deurwaerdère P, Spampinato U. Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol Psychiatry 2006; 59(6): 568-75.
69. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 2006; 71(4): 521-9.
70. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 2001; 299(1): 83-9.
71. Vanover KE, Harvey SC, Son T, et al. Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist. J Pharmacol Exp Ther 2004; 310(3): 943-51.
72. Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm 2008; 65(5): 403-13.
73. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007; 33(5): 1100-19.
74. Schotte A, Janssen P, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124(1-2): 57-73.
75. Turkoz I, Bossie C, Lindenmayer J, Scooler N, Canuso C. Paliperidone ER and oral risperidone in patients with schizophrenia: a compoarative database analysis. BMC Psychiatry 2011; 11: 21.
76. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 35: 218-26.
77. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51(1): 80-8.
78. Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R, 3R)-dihydroxybutanedioate (2: 1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006; 317(2): 910-18.
79. Snigdha S, Horiguchi M, Huang M, et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2010; 332(2): 622-31.
80. Gardell LR, Vanover KE, Pounds L, et al. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 2007; 322(2): 862-70.
81. Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008; 9(18): 3251-9.
82. Robarts C. ACP-103, a 5-HT2A receptor inverse agonist. Curr Opin Investig Drugs 2006; 7(7): 653-60.
83. Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance ebficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res 2012; 141(2-3): 144-52.
84. Parra S, Bond RA. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Curr Opin Pharmacol 2007; 7(2): 146-50.
85. Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Behav Pharmacol 2012; 23(4): 426-33.
86. McFarland K, Price DL, Bonhaus DW. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. Behav Pharmacol 2011; 22(7): 681-92.
87. Navailles S, Lagière M, Roumegous A, et al. Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease. Int J Neuropsychopharmacol 2013; 16(3): 593-606.
88. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebocontrolled phase 3 trial. Lancet 2014; 383(9916): 533-40.
89. Akam E, Strange PG. Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol 2004; 67(11): 2039-45.
90. Rosenzweig-Lipson S, Comery TA, Marquis KL, Gross J, Dunlop J. 5-HT2C agonists as therapeutics for the treatment of schizophrenia. Hanb Exp Pharmacol 2012; 213: 147-65.
91. Shen JH, Zhao Y, Rosenzweig-Lipson S, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res 2014; 53: 14-22.
92. Liu J, Ogden A, Comery TA, Spiros A, Roberts P, Geerts H. Prediction of efficacy of vabixaserin, a 5-HT2C agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model. CPT Pharmacometrics Syst Pharmacol 2014; 3: e111.